Gland Pharma Limited

NSEI:GLAND 株式レポート

時価総額:₹294.4b

Gland Pharma 配当と自社株買い

配当金 基準チェック /36

Gland Pharma配当を支払う会社であり、現在の利回りは1.12%で、収益によって十分にカバーされています。

主要情報

1.1%

配当利回り

-0.009%

バイバック利回り

総株主利回り1.1%
将来の配当利回り0.4%
配当成長n/a
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金₹20.000
配当性向46%

最近の配当と自社株買いの更新

更新なし

Recent updates

Gland Pharma Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next

Nov 07
Gland Pharma Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next

Gland Pharma Limited (NSE:GLAND) Shares Could Be 23% Above Their Intrinsic Value Estimate

Oct 26
Gland Pharma Limited (NSE:GLAND) Shares Could Be 23% Above Their Intrinsic Value Estimate

Gland Pharma (NSE:GLAND) Has A Pretty Healthy Balance Sheet

Oct 01
Gland Pharma (NSE:GLAND) Has A Pretty Healthy Balance Sheet

Investors Still Waiting For A Pull Back In Gland Pharma Limited (NSE:GLAND)

Sep 05
Investors Still Waiting For A Pull Back In Gland Pharma Limited (NSE:GLAND)

Gland Pharma Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 09
Gland Pharma Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Does Gland Pharma (NSE:GLAND) Have A Healthy Balance Sheet?

Jun 22
Does Gland Pharma (NSE:GLAND) Have A Healthy Balance Sheet?

Earnings Miss: Gland Pharma Limited Missed EPS By 15% And Analysts Are Revising Their Forecasts

May 25
Earnings Miss: Gland Pharma Limited Missed EPS By 15% And Analysts Are Revising Their Forecasts

Is Gland Pharma (NSE:GLAND) A Risky Investment?

Mar 19
Is Gland Pharma (NSE:GLAND) A Risky Investment?

Gland Pharma Limited's (NSE:GLAND) Share Price Matching Investor Opinion

Feb 16
Gland Pharma Limited's (NSE:GLAND) Share Price Matching Investor Opinion

Analysts' Revenue Estimates For Gland Pharma Limited (NSE:GLAND) Are Surging Higher

May 20
Analysts' Revenue Estimates For Gland Pharma Limited (NSE:GLAND) Are Surging Higher

Is Gland Pharma Limited (NSE:GLAND) Expensive For A Reason? A Look At Its Intrinsic Value

Feb 07
Is Gland Pharma Limited (NSE:GLAND) Expensive For A Reason? A Look At Its Intrinsic Value

Analysts Just Slashed Their Gland Pharma Limited (NSE:GLAND) EPS Numbers

Jul 22
Analysts Just Slashed Their Gland Pharma Limited (NSE:GLAND) EPS Numbers

Does This Valuation Of Gland Pharma Limited (NSE:GLAND) Imply Investors Are Overpaying?

Jul 14
Does This Valuation Of Gland Pharma Limited (NSE:GLAND) Imply Investors Are Overpaying?

Is Now The Time To Put Gland Pharma (NSE:GLAND) On Your Watchlist?

Feb 08
Is Now The Time To Put Gland Pharma (NSE:GLAND) On Your Watchlist?

決済の安定と成長

配当データの取得

安定した配当: GLANDは配当の支払いを開始したばかりなので、配当金の支払いが安定しているかどうかを判断するのは時期尚早です。

増加する配当: GLANDは配当の支払いを開始したばかりなので、配当金が増加するかどうかを判断するのは時期尚早です。


配当利回り対市場

Gland Pharma 配当利回り対市場
GLAND 配当利回りは市場と比べてどうか?
セグメント配当利回り
会社 (GLAND)1.1%
市場下位25% (IN)0.3%
市場トップ25% (IN)1.2%
業界平均 (Pharmaceuticals)0.7%
アナリスト予想 (GLAND) (最長3年)0.4%

注目すべき配当: GLANDの配当金 ( 1.12% ) はIndian市場の配当金支払者の下位 25% ( 0.25% ) よりも高くなっています。

高配当: GLANDの配当金 ( 1.12% ) はIndian市場の配当金支払者の上位 25% ( 1.17% ) と比較すると低いです。


株主への利益配当

収益カバレッジ: GLANDの 配当性向 ( 45.6% ) はかなり低いため、配当金の支払いは利益によって十分にカバーされます。


株主配当金

キャッシュフローカバレッジ: GLANDの 現金配当性向 ( 40.2% ) は比較的低く、配当金の支払いはキャッシュフローによって十分にカバーされています。


高配当企業の発掘